RxDoctor Payments Data

Ravikanth Reddy Yalamuri, MD

Internal Medicine · San Antonio, TXNPI 1568791010

Payments from drug & device makers

$300in general payments, 2019–2025

Across 7 payments — averaging $42.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$134
  • Medtronic$106
  • Lilly USA, LLC$28
  • Urovant Sciences Inc$20
  • E.r. Squibb & Sons, L.L.C.$12

What the payments were for

  • Food & beverage$300100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$300 in reported general payments places this provider in the 50th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$29,971,354
Medicare patients
725
Services billed
18,055

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban653$204,572
MyrbetriqMirabegron450$107,424
NuplazidPimavanserin Tartrate22$52,946
OzempicSemaglutide49$50,574
XifaxanRifaximin29$38,741
GemtesaVibegron153$37,208
XareltoRivaroxaban114$35,995
Abilify MaintenaAripiprazole11$32,825
Risperdal ConstaRisperidone Microspheres29$27,605
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$27,144
NuedextaDextromethorphan Hbr/Quinidine32$20,908
JardianceEmpagliflozin67$20,817
TrulicityDulaglutide20$20,249
JanuviaSitagliptin Phosphate62$17,756
FarxigaDapagliflozin Propanediol55$16,960

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$28$20,24920 claims
NovartisEntresto$134$9,76422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →